Immune Checkpoint Inhibitors in Metastatic Clear-cell Renal Cell Carcinoma: Is PD-L1 Expression Useful?

Eur Urol. 2021 Jun;79(6):793-795. doi: 10.1016/j.eururo.2021.02.040. Epub 2021 Mar 26.

Authors

Laurence Albiges¹, Ronan Flippot², Bernard Escudier²

Affiliations

¹ Genito-Urinary Oncology Unit, Department of Medical Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France. Electronic address: laurence.albiges@gustaveroussy.fr.
² Genito-Urinary Oncology Unit, Department of Medical Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France.

PMID: 33773871
DOI: 10.1016/j.eururo.2021.02.040

No abstract available

Publication types

Editorial
Comment

MeSH terms

B7-H1 Antigen
Carcinoma, Renal Cell* / drug therapy
Humans
Immune Checkpoint Inhibitors
Kidney Neoplasms* / drug therapy
Programmed Cell Death 1 Receptor

Substances

B7-H1 Antigen
Immune Checkpoint Inhibitors
Programmed Cell Death 1 Receptor